Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127189521 | 12718952 | 1 | I | 2005 | 20150219 | 20160906 | 20160906 | EXP | US-ASTRAZENECA-2015SE17358 | ASTRAZENECA | 64.00 | YR | M | Y | 86.20000 | KG | 20160907 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127189521 | 12718952 | 1 | PS | NEXIUM | ESOMEPRAZOLE MAGNESIUM | 1 | Oral | 21153 | 40 | MG | CAPSULE | QD | |||||||
| 127189521 | 12718952 | 2 | SS | OMEPRAZOLE. | OMEPRAZOLE | 1 | Oral | EVERY OTHER DAY | U | 0 | |||||||||
| 127189521 | 12718952 | 3 | SS | OMEPRAZOLE. | OMEPRAZOLE | 1 | Oral | EVERY OTHER DAY | U | 0 | |||||||||
| 127189521 | 12718952 | 4 | SS | OMEPRAZOLE. | OMEPRAZOLE | 1 | Oral | U | 0 | 40 | MG | QD | |||||||
| 127189521 | 12718952 | 5 | SS | OMEPRAZOLE. | OMEPRAZOLE | 1 | Oral | U | 0 | 40 | MG | QD | |||||||
| 127189521 | 12718952 | 6 | SS | NEXIUM | ESOMEPRAZOLE MAGNESIUM | 1 | Oral | U | 0 | 2 | DF | QD | |||||||
| 127189521 | 12718952 | 7 | SS | NEXIUM | ESOMEPRAZOLE MAGNESIUM | 1 | Oral | U | 0 | 2 | DF | QD | |||||||
| 127189521 | 12718952 | 8 | C | FLAX SEED | FLAX SEED | 1 | Oral | 0 | 1200 | MG | QD | ||||||||
| 127189521 | 12718952 | 9 | C | COQ10 | UBIDECARENONE | 1 | Oral | DAILY | 0 | ||||||||||
| 127189521 | 12718952 | 10 | C | VITAMIN C | ASCORBIC ACID | 1 | Oral | 0 | 1000 | MG | QD | ||||||||
| 127189521 | 12718952 | 11 | C | VITAMIN D3 | CHOLECALCIFEROL | 1 | Oral | 0 | 2000 | IU | QD | ||||||||
| 127189521 | 12718952 | 12 | C | OMEGA 3 | OMEGA-3 FATTY ACIDS | 1 | Oral | DAILY | 0 | ||||||||||
| 127189521 | 12718952 | 13 | C | SUPER B WITH VITAMIN C | 2 | Oral | DAILY | 0 | |||||||||||
| 127189521 | 12718952 | 14 | C | BABY ASPIRIN | ASPIRIN | 1 | Oral | 0 | 81 | MG | QOD | ||||||||
| 127189521 | 12718952 | 15 | C | MULTIVITAMIN | VITAMINS | 1 | Oral | 0 | 1 | DF | QD | ||||||||
| 127189521 | 12718952 | 16 | C | SAW PALMETTO | SAW PALMETTO | 1 | Oral | DAILY | 0 | ||||||||||
| 127189521 | 12718952 | 17 | C | FAMOTIDINE. | FAMOTIDINE | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127189521 | 12718952 | 1 | Gastrooesophageal reflux disease |
| 127189521 | 12718952 | 2 | Gastrooesophageal reflux disease |
| 127189521 | 12718952 | 3 | Gastrooesophageal reflux disease |
| 127189521 | 12718952 | 4 | Gastrooesophageal reflux disease |
| 127189521 | 12718952 | 5 | Gastrooesophageal reflux disease |
| 127189521 | 12718952 | 6 | Gastrooesophageal reflux disease |
| 127189521 | 12718952 | 7 | Gastrooesophageal reflux disease |
| 127189521 | 12718952 | 9 | Cardiac disorder |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127189521 | 12718952 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127189521 | 12718952 | Drug ineffective | |
| 127189521 | 12718952 | Intentional product misuse | |
| 127189521 | 12718952 | Internal haemorrhage |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127189521 | 12718952 | 1 | 2005 | 0 | ||
| 127189521 | 12718952 | 2 | 2015 | 0 | ||
| 127189521 | 12718952 | 3 | 2015 | 0 | ||
| 127189521 | 12718952 | 4 | 2015 | 0 | ||
| 127189521 | 12718952 | 5 | 2015 | 0 |